1. Home
  2. IMMP vs HTCO Comparison

IMMP vs HTCO Comparison

Compare IMMP & HTCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • HTCO
  • Stock Information
  • Founded
  • IMMP 1987
  • HTCO N/A
  • Country
  • IMMP Australia
  • HTCO Hong Kong
  • Employees
  • IMMP N/A
  • HTCO N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • HTCO
  • Sector
  • IMMP Health Care
  • HTCO
  • Exchange
  • IMMP Nasdaq
  • HTCO NYSE
  • Market Cap
  • IMMP 304.0M
  • HTCO 360.8M
  • IPO Year
  • IMMP N/A
  • HTCO N/A
  • Fundamental
  • Price
  • IMMP $1.92
  • HTCO $2.94
  • Analyst Decision
  • IMMP Buy
  • HTCO
  • Analyst Count
  • IMMP 2
  • HTCO 0
  • Target Price
  • IMMP $8.50
  • HTCO N/A
  • AVG Volume (30 Days)
  • IMMP 72.2K
  • HTCO 88.1K
  • Earning Date
  • IMMP 03-03-2025
  • HTCO 01-01-0001
  • Dividend Yield
  • IMMP N/A
  • HTCO N/A
  • EPS Growth
  • IMMP N/A
  • HTCO N/A
  • EPS
  • IMMP N/A
  • HTCO N/A
  • Revenue
  • IMMP $2,563,302.00
  • HTCO $80,567,672.00
  • Revenue This Year
  • IMMP N/A
  • HTCO N/A
  • Revenue Next Year
  • IMMP $47.79
  • HTCO N/A
  • P/E Ratio
  • IMMP N/A
  • HTCO N/A
  • Revenue Growth
  • IMMP 9.59
  • HTCO N/A
  • 52 Week Low
  • IMMP $1.66
  • HTCO $0.21
  • 52 Week High
  • IMMP $3.34
  • HTCO $4.50
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 43.56
  • HTCO N/A
  • Support Level
  • IMMP $1.94
  • HTCO N/A
  • Resistance Level
  • IMMP $2.08
  • HTCO N/A
  • Average True Range (ATR)
  • IMMP 0.08
  • HTCO 0.00
  • MACD
  • IMMP -0.00
  • HTCO 0.00
  • Stochastic Oscillator
  • IMMP 20.00
  • HTCO 0.00

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

About HTCO CARAVELLE INTERNATIONAL GROUP

Caravelle International Group is an international operator of ocean transportation services. It is engaged in the seaborne transportation service under voyage contracts as well as vessel service for and on behalf of ship owners. The company has two operating segments namely, ocean transport and Heating business. The company derives the majority of its revenue from the Ocean transportation business. The company derives freight revenue from voyage contracts and provides vessel service.

Share on Social Networks: